Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Immunophenotypic Characteristics of CD34+ Cells According to Genetic Markers in Acute Myeloid Leukemias with Normal Karyotype.

Mauricio A Chandía, MD, Ma Belén Vidriales, MD, PhD, Carmen Chillón, PhD, Marcos González, MD, PhD, Norma Gutiérrez, MD, PhD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): 2554.

https://doi.org/10.1182/blood.V120.21.2554.2554

Published: 2012

Journal Articles

Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14.

Ana E Rodríguez, Jose Ángel Hernández-Rivas, Alberto Risueño, Encarna Fermiñán, Natalia de las Heras, Alfonso Garcia de Coca, Carlos Aguilar, Juan Nicolás Rodríguez, Josefina Galende, Javier de las Rivas, Jesús F San Miguel, MD, Marcos González, Jesús M Hernández-Rivas

Blood (2012) 120 (21): 2871.

https://doi.org/10.1182/blood.V120.21.2871.2871

Published: 2012

Journal Articles

A Targeted Resequencing Study Allows the Detection of a Common Polymorphism At Mirna-223 Binding Site in 3′Untranslated Region Which Deregulates HSP90B1 Expression in Chronic Lymphocytic Leukemia

Ana E Rodríguez, Dalia Qwaider, Rocío Benito, PhD, Irena Misiewicz-Krzeminska, María Hernández-Sánchez, M Eugenia Sarasquete, Jesús F San Miguel, MD, Jose Ángel Hernández-Rivas, Norma Gutierrez, Jesús M Hernández-Rivas

Blood (2012) 120 (21): 1776.

https://doi.org/10.1182/blood.V120.21.1776.1776

Published: 2012

Journal Articles

Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease

Lorenzo Melchor, PhD, Brian A Walker, BSc, PhD, Christopher P Wardell, PhD, Annamaria Brioli, MD, Martin F Kaiser, MD, Lucía López-Corral, MD, Sean Humphray, Lisa Murray, Mark Ross, David Bentley, Ramón García-Sanz, Jesús F San Miguel, MD, PhD, Faith E. Davies, MD, David Gonzalez, PhD, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 3941.

https://doi.org/10.1182/blood.V120.21.3941.3941

Published: 2012

Journal Articles

Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

Blood (2012) 120 (21): 3827.

https://doi.org/10.1182/blood.V120.21.3827.3827

Published: 2012

Journal Articles

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez, Dalia Quwaider, Enrique M Ocio, MD, PhD, Laura San-Segundo, Teresa Paíno, Juan F Blanco, Allison J Berger, PhD, Atanasio Pandiella, MD, PhD, Jesús F San-Miguel, MD, PhD, Mercedes Garayoa

Blood (2012) 120 (21): 4014.

https://doi.org/10.1182/blood.V120.21.4014.4014

Published: 2012

Journal Articles

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Blood (2012) 120 (21): 749.

https://doi.org/10.1182/blood.V120.21.749.749

Published: 2012

Journal Articles

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Meletios A. Dimopoulos, MD, Martha Q Lacy, MD, Philippe Moreau, MD, Katja C Weisel, MD, Kevin W. Song, MD, FRCPC, Michel Delforge, MD, PhD, Lionel Karlin, MD, Hartmut Goldschmidt, MD, Anne Banos, MD, Albert Oriol, MD, Xin Yu, PhD, Lars Sternas, MD, Christian J. Jacques, MD, Mohamed Zaki, MD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): LBA-6.

https://doi.org/10.1182/blood.V120.21.LBA-6.LBA-6

Published: 2012

Journal Articles

Prognostic Impact of the Number of Methylated Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemias Treated with 5-Azacytidine

María Abáigar, Fernando Ramos, MD, PhD, MPH, Rocío Benito, PhD, María Díez-Campelo, MD, PhD, Javier Sánchez-del-Real, MD, Lourdes Hermosin, MD, Juan N Rodríguez, MD, Carlos Aguilar, MD, Isabel Recio, MD, Jose M Alonso, MD, Natalia de-las-Heras, MD, Marta Megido, MD, Marta Fuertes, MD, Consuelo Cañizo, MD, PhD, Jesús M Hernández, MD, PhD, Jesús F San Miguel, MD, PhD

Blood (2012) 120 (21): 1717.

https://doi.org/10.1182/blood.V120.21.1717.1717

Published: 2012

Journal Articles

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Enrique M Ocio, MD, PhD, Pilar Herrera, MD, PhD, Teresa Olave, MD, Salut Brunet, Albert Oriol, Maria-Pilar Martínez-Sánchez, Miguel A. Sanz, MD, PhD, Marta Mateos, MD, Pilar Aliseda, MD, Ivo J. Winiger, MD, Sushant Hardikar, Maria Victoria Mateos, MD, PhD, Javier Lopez, Jesús F. San-Miguel, MD, PhD

Blood (2012) 120 (21): 1512.

https://doi.org/10.1182/blood.V120.21.1512.1512

Published: 2012

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Blood (2011) 118 (21): 3938.

https://doi.org/10.1182/blood.V118.21.3938.3938

Published: 2011

Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Blood (2011) 118 (21): 3976.

https://doi.org/10.1182/blood.V118.21.3976.3976

Published: 2011

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

Journal Articles

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

Enrique M Ocio, Diego Fernández-Lázaro, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Mercedes Garayoa, Teresa Paíno, Antonio Garcia-Gomez, Norma C. Gutierrez, Manuel Delgado, Juan C. Montero, Nuria Quintana, Jose Luis García, Atanasio Pandiella, Jesús F. San Miguel, MD, PhD

Blood (2011) 118 (21): 134.

https://doi.org/10.1182/blood.V118.21.134.134

Published: 2011

Journal Articles

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD, Hartmut Goldschmidt, Deyanira Corzo, MD, Carol Satler, Dixie-Lee Esseltine, MD, FRCPC, Rachel Neuwirth, MS, Maria Ponsillo, MD, Andrew Z Cakana, MD, FRCPath, Jay King, MD, William M Deraedt, PhD, Avinash Desai, Yana Lutska, Dina Gifkins, PhD, Kevin Liu, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 2933.

https://doi.org/10.1182/blood.V118.21.2933.2933

Published: 2011

Journal Articles

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Blood (2009) 114 (22): 2655.

https://doi.org/10.1182/blood.V114.22.2655.2655

Published: 2009

Journal Articles

A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.

Blood (2009) 114 (22): 3.

https://doi.org/10.1182/blood.V114.22.3.3

Published: 2009

Journal Articles

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Jesús F. San-Miguel, MD, PhD, Orhan Sezer, MD, PhD, David Siegel, Andreas Guenther, MD, Maria-Victoria Mateos, MD, PhD, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Michele Cavo, MD, Joan Blade, MD, Mario Boccadoro, MD, Bourras R. Bengoudifa, Martin Klebsattel, PhD, Priscille M. Bourquelot, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3852.

https://doi.org/10.1182/blood.V114.22.3852.3852

Published: 2009

Journal Articles

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Antonio Garcia-Gomez, Mercedes Garayoa, Enrique M. Ocio, Edvan Crusoe, Diego Fernández, Teresa Paíno, Laura San Segundo, Juan C. Montero, Stela Álvarez-Fernández, Juan F. Blanco, Fermin M. Sanchez-Guijo, Felix T. Garzon, Atanasio Pandiella, Jesús F. San-Miguel, MD, PhD

Blood (2009) 114 (22): 3834.

https://doi.org/10.1182/blood.V114.22.3834.3834

Published: 2009

NARROW

Immunophenotypic Characteristics of CD34+ Cells According to Genetic Markers in Acute Myeloid Leukemias with Normal Karyotype.

Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14.

A Targeted Resequencing Study Allows the Detection of a Common Polymorphism At Mirna-223 Binding Site in 3′Untranslated Region Which Deregulates HSP90B1 Expression in Chronic Lymphocytic Leukemia

Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease

Array CGH As a Complementary Tool in the Diagnosis of Myelodysplastic Syndromes

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

Prognostic Impact of the Number of Methylated Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemias Treated with 5-Azacytidine

Initial Results of the Phase I/II Panobidara Study of Panobinostat in Combination with Idarubicin and Cytarabine in Patients Aged 65 Years or Older with Newly Diagnosed Acute Myeloblastic Leukaemia (AML)

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

Reversibility of the Resistance to Lenalidomide and Pomalidomide and Absence of Cross-Resistance in a Murine Model of MM

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Dasatinib Promotes Osteoprogenitor Differentiation and Inhibition of Osteoclastogenesis: Rationale for Treatment of Myeloma Bone Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only